Postbiotic ABB C3: A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
Placebo: A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
Follow-up Postbiotic ABB C3 (Optional): Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
Study summary
This study investigates the effects of a postbiotic combination called ABB C3 on reducing body fat and improving metabolic health in children and teenagers. The study consists of a 3-month trial with half participants taking ABB C3 and the other half a placebo, monitoring body composition and blood markers. Afterward, participants can continue with ABB C3 for an additional 3 months. The goal is to determine if ABB C3 is a safe and effective way to help young people improve their health by reducing body fat.
Eligibility
Sex
ALL
Min age
8 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* Age between 8- and 18-year-old
* Obesity (BMI-SDS \> 2)
Exclusion Criteria:
* Antibiotic or pre/pro/postbiotic consumption 2 - 4 weeks prior to starting the study
* Chronic diseases affecting glucose or lipid metabolism
* Chronic medication affecting glucose or lipid metabolism, or inducing a pro-inflammatory state
* History of bariatric surgery
* Diabetes requiring insulin treatment
* Severe intellectual disability
* Pregnancy
* Individuals taking medications that may alter appetite or weight, with a recent change in prescription within the last 3 months or anticipated changes during the 2 months of participation
Primary outcome measure(s)
Incidence of Adverse Events — Baseline, 1.5 months, 3 months Treatment safety and tolerability will be evaluated by assessing differences in the incidence of potential adverse events between groups, focusing on gastrointestinal symptoms.
Change in adiposity (% fat body mass) — 3 months Fat body mass (adiposity) will be assessed by dual energy x-ray absorptiometry (DXA) scan at baseline and 3 months and differences will be assessed
Change in blood glycated hemoglobin (HbA1c) levels — 3 months Blood tests will be performed at baseline and 3 months and HbA1c (%) levels quantified.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
